We advised AMR Action Fund on its investment in BioVersys

Davis Polk advised AMR Action Fund on its participation in the initial public offering of BioVersys AG shares on the SIX Swiss Exchange and a concurrent private placement by BioVersys as to matters of U.S. law. BioVersys issued 2,222,221 shares in the initial public offering at CHF 36.00 per share, for total gross proceeds of CHF 80 million. AMR Action Fund, L.P. and AMR Action Fund, SCSp (together, the “AMR Action Fund”) entered into separate agreements with BioVersys to purchase approximately CHF 22 million of shares. The shares are traded on the SIX Swiss Exchange under the symbol “BIOV.”

The AMR Action Fund is a mission-driven venture capital fund investing in antibiotics, antifungals and other antimicrobial technologies.

BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria.

The Davis Polk corporate team included partner Stephen A. Byeff and associate Joyce Kim. Partner Michael S. Hong, counsel Benjamin Milder and associate June (Juyeon) Han provided investment management advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post